ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Linc-ROR drive adriamycin resistance by targeting AP-2α/Wnt/β-catenin axis in hepatocellular carcinoma

Shi, Chuan-Jian; Lv, Min-Yi; Deng, Li-Qiang; Zeng, Wei-Qiang; Fu, Wei-Ming*; Zhang, Jin-Fang*广州中医药大学; 南方医科大学
Cell Biology and Toxicology2023-8DOI: 10.1007/s10565-022-09777-3
1被引3阅读
引用收藏
分享

摘要

Adriamycin is widely used as a chemotherapeutic strategy for advanced hepatocellular carcinoma (HCC). However, the clinical response was disappointing because of the acquired drug resistance with long-term usage. Revealing the underlying mechanism could provide promising therapeutics for the drug-resistant patients. The recently identified linc-ROR (long intergenic non-protein-coding RNA, regulator of reprogramming) has been found to be an oncogene in various cancers, and it also demonstrated to mediate drug resistance and metastasis. We thereby wonder whether this lincRNA could mediate adriamycin chemoresistance in HCC. In this study, linc-ROR was found to be upregulated in adriamycin-resistant HCC cells. And its overexpression accelerated epithelial-mesenchymal transition (EMT) program and adriamycin resistance. Conversely, its silence suppressed EMT and made HCC cells sensitize to adriamycin in vitro and in vivo. Further investigation revealed that linc-ROR physically interacted with AP-2 alpha, mediated its stability by a post-translational modification manner, and sequentially activated Wnt/beta-catenin pathway. Furthermore, linc-ROR expression was positively associated with beta-catenin expression in human clinical specimens. Taken together, linc-ROR promoted tumorigenesis and adriamycin resistance in HCC via a linc-ROR/AP-2 alpha/Wnt/beta-catenin axis, which could be developed as a potential therapeutic target for the adriamycin-resistant patients.

学科与关键词

关键词
Hepatocellular carcinomaLinc-RORWnt/beta-catenin pathwayAP-2 alphaAdriamycin resistance
相关
加载中…
  • Dimeric oxyberberine CT4-1 targets LINC02331 to induce cytotoxicity and inhibit chemoresistance via suppressing Wnt/β-catenin signaling in hepatocellular carcinoma
    Lin, Xian; Chen, Jian; Li, Xin; Chen, Dong; Luo, Kaixuan; Deng, Yongxing; Yang, Dinghua*; Huang, Zunnan*; Tao, Cheng*Archives of Toxicology, 2023, 97(6): 1627-1647.被引 2
  • Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
    Zhang, Yuxin; Zhang, Yujie; Tao, Haisu; Zhu, Jinghan; Lu, Yuanxiang; Cheng, Fangling; Xiong, Yixiao; Liu, Junjie; Cai, Guangzhen; Zhang, Zhanguo*; Liang, Huifang*; Chen, Yifa*; Zhang, Wanguang*Cancer Letters, 2023, 576: 216405.被引 1
  • TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib
    Wang, Zongwen; Zhu, Qiankun; Li, Xiaodong; Ren, Xiaohang; Li, Jingtao; Zhang, Yao; Zeng, Shicong; Xu, Lishan; Dong, Xiaoqun*; Zhai, Bo*American Journal of Cancer Research, 2022, 12(9): 4343-+.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
Cell Biology and Toxicology
发表日期
2023-08
卷期
第 39 卷, 第 4 期
页码
1735-1752
DOI
10.1007/s10565-022-09777-3
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773066, 81772404]; Natural Science Foundation of Guangdong Province [2020A1515010961, 2021A1515012111]

作者

  • S

    Shi, Chuan-Jian (第一作者)

    new · southern med univ

  • L

    Lv, Min-Yi

    new · southern med univ · shenzhen matern & child healthcare hosp

查看全部 6 位作者收起作者
  • D

    Deng, Li-Qiang

    new · southern med univ

  • Z

    Zeng, Wei-Qiang

    new · southern med univ

  • F

    Fu, Wei-Ming (通讯)

    new · southern med univ

  • Z

    Zhang, Jin-Fang (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417